NCT05462535View on ClinicalTrials.gov

An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet

CompletedOBSERVATIONAL
Enrollment

4,785

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions
Hypertension,Essential
Interventions
DRUG

Amosartan Plus Tab.

Amosartan Plus Tab., Once daily administered per the locally approved product information

Trial Locations (1)

05545

Hanmi Pharmaceutical Company Limited, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05462535 - An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet | Biotech Hunter | Biotech Hunter